Skip to Content

Firdapse Approval Status

  • FDA approved: No
  • Brand name: Firdapse
  • Generic name: amifampridine phosphate
  • Company: Catalyst Pharmaceuticals, Inc.
  • Treatment for: Lambert Eaton Myasthenic Syndrome (LEMS); Congenital Myasthenic Syndromes (CMS)

Firdapse (amifampridine phosphate) is a neuronal potassium channel blocker in development for the treatment of Lambert Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).

Development Status and FDA Approval Process for Firdapse

Mar 29, 2018Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse for Treatment of Lambert-Eaton Myasthenic Syndrome
Feb 12, 2018Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse
Dec  8, 2016Catalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients with Congenital Myasthenic Syndromes
Apr 26, 2016Catalyst Pharmaceuticals Provides Regulatory Update on Firdapse
Feb 17, 2016Catalyst Pharmaceuticals Receives Refusal to File Letter From the FDA on Its NDA for Firdapse
Dec 17, 2015Catalyst Pharmaceuticals Completes NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.